BPC-157 Dosage Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Educational information only — not medical advice. BPC-157 is not FDA-approved for any medical use. Every dose, protocol, and chart below is a summary of published research and physician-directed practice, written to inform a conversation with a licensed provider — not a set of self-administration instructions. Peptide therapy at Beverly Hills Rejuvenation Center is physician-supervised. Do not begin, adjust, or stop any peptide protocol without a qualified prescriber.

Quick BPC-157 Dosing Summary

In the published research literature and in physician-directed practice, BPC-157 is most commonly dosed at 250–500 mcg per day by subcutaneous injection, given once or twice daily in a 4–8 week cycle. For musculoskeletal injuries the injection is often placed near the affected tissue; for gut-related use an oral capsule (typically 500–1,500 mcg/day) is frequently chosen. These are provider-directed ranges, not a universal prescription — the right dose depends on indication, body weight, and clinical judgment.

Schedule a Peptide Therapy Consultation →

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide made of 15 amino acids — a “pentadecapeptide.” It is a partial sequence derived from a protein found in human gastric juice, which is why it is often described as a “stable gastric pentadecapeptide.” Researchers first characterized it in the 1990s while studying the stomach’s own ability to protect and repair its lining.

The Peptide’s Origin and Structure

Unlike growth-hormone-releasing peptides such as CJC-1295 or ipamorelin, BPC-157 is not a hormone and does not act on the pituitary. It is a small, relatively stable fragment that has been studied primarily for tissue protection and repair. In laboratory work it is noted for being unusually stable in gastric acid — a property that has driven interest in oral formulations.

How BPC-157 Is Thought to Work

The proposed mechanisms are drawn almost entirely from animal and cell-culture studies. In those models, BPC-157 appears to promote angiogenesis (new blood-vessel formation) through increased expression of VEGF and its receptor VEGFR2, to support fibroblast migration and tendon-cell outgrowth, to modulate the nitric-oxide system, and to influence growth-hormone-receptor expression in injured tissue. The Seiwerth group at the University of Zagreb has published extensively on these pathways in the context of wound healing. It is important to be clear that these are mechanistic findings in animals, not proven clinical effects in people.

Systemic vs. Local Action

One practical distinction runs through this entire guide: BPC-157 can be used with a systemic intent (a general dose absorbed body-wide) or a local intent (injected near a specific injury in the hope of concentrating effect). Both approaches appear throughout the research literature, and the choice shapes injection-site selection, dose, and frequency — all covered below.

Why BPC-157 Gets So Much Attention

Three features explain the outsized interest. First, the breadth of the preclinical literature is unusual: animal studies span tendon, ligament, muscle, bone, gut, nerve, and even organ injury, which is why BPC-157 is marketed as a near-universal “healing” peptide. Second, its oral stability is atypical for a peptide, opening a needle-free route that most peptides cannot offer. Third, it has an apparently benign short-term tolerability profile in the reports that exist. None of those three features is the same as proven human efficacy, and this guide keeps that distinction front and center — but they are the reasons BPC-157 is one of the most-searched peptides in recovery medicine.

What BPC-157 Is Not

To set expectations correctly: BPC-157 is not an anabolic steroid, a growth hormone, or a growth-hormone secretagogue — it will not directly build muscle or raise IGF-1 the way the GH-axis peptides do. It is not a painkiller, an anti-inflammatory drug in the NSAID sense, or an approved treatment for any condition. It is best understood as a research-stage tissue-repair peptide that a physician may consider as an adjunct to — never a replacement for — standard care such as rest, rehabilitation, physical therapy, and appropriate medical treatment.

BPC-157 Dosing Protocols Based on Clinical Research

There is no FDA-approved dose of BPC-157 because there is no FDA-approved BPC-157 product. The ranges below are synthesized from the preclinical literature and from how physician-supervised clinics translate that literature into practice. They are provider-directed education, not a protocol to run on your own.

Standard Dosing Ranges

The most frequently cited daily dose is 250–500 mcg by subcutaneous injection, given either once daily or split into a morning and evening dose. Many providers begin at the low end (250 mcg/day) to assess tolerance before considering the higher end. The table below frames conservative, standard, and higher-intensity approaches as tiers.

Indication-Specific Dosing: Tendon, Ligament & Muscle

For tendon, ligament, and muscle injuries, the literature and clinical practice tend to favor injecting near the injured tissue — commonly described as within roughly 2–5 cm of the affected area — under the reasoning that local delivery concentrates the peptide where repair is needed. A representative practical framing:

The rodent evidence base for tendon and myotendinous-junction healing is where BPC-157 has been studied most — for example, work on the disabled myotendinous junction in rats (Japjec et al., 2021) reported improved healing outcomes with the peptide. Human data for these uses remains extremely limited, as discussed under Clinical Trial Data.

Indication-Specific Dosing: Gut & GI Healing

BPC-157’s origin story is gastrointestinal, and gut-focused use is one of its highest-interest applications (NSAID-related irritation, inflammatory bowel conditions, and general GI-lining support have all driven searches). For gut indications, an oral route is frequently chosen on the logic that the peptide is delivered directly to the GI tract, and it is prized for stability in stomach acid.

The proposed indication that has driven BPC-157’s formal regulatory nomination (see the FDA section) is ulcerative colitis — a reminder that the gut is where the most serious clinical interest sits, and also where the most careful physician oversight is warranted.

Indication-Specific Dosing: Post-Surgical Recovery

Some providers apply BPC-157 in a post-surgical or post-injury recovery context, generally at standard systemic doses (250–500 mcg/day) for a defined cycle. This is entirely provider-directed and must be coordinated with the surgical team — angiogenic activity around a fresh surgical site, healing hardware, or any active or suspected malignancy is exactly where the theoretical concerns discussed later become clinically relevant. Timing relative to surgery matters too: some clinicians prefer to wait until the acute post-operative window has passed and the surgeon has cleared the patient, rather than introducing a pro-angiogenic peptide into an actively healing surgical bed. This is a judgment call that belongs to the treating physicians, not to a generic protocol.

How Body Weight and Injury Severity Factor In

Because much of the dosing rationale derives from weight-based animal work (roughly 10 mcg/kg scaled down), body weight is one lever a provider may consider: a larger patient sits nearer the top of the 250–500 mcg range, a smaller patient nearer the bottom. Injury severity and acuity are the second lever — a fresh, significant soft-tissue injury may be dosed toward the higher, twice-daily end for a short, defined window, while a chronic nagging issue or a maintenance goal is more often kept at the conservative end. The consistent theme across all of it is start low, reassess, and escalate only with a reason, because there is no human trial that has defined an “optimal” dose to anchor to.

Research-Based Protocols and Allometric Scaling

Many of the human dose ranges in circulation are derived by allometric scaling from rodent studies that used roughly 10 mcg/kg. Scaled to a human, that math lands in the low-hundreds-of-micrograms-per-day range, which is broadly consistent with the 250–500 mcg/day figures used clinically. Scaling is an approximation, not a validated human dose — it is one of the reasons the field emphasizes conservative starting doses and physician supervision.

Clinical Trial Data and the Human Evidence Gap

Honest evidence framing matters here more than almost anywhere in peptide therapy. A 2025 systematic review in the HSS Journal (Vasireddi et al.) screened the literature and identified 36 BPC-157 studies — 35 were preclinical (animal or cell-culture) and only one was clinical, a small retrospective case series of intra-articular BPC-157 for knee pain in which 7 of 12 patients reported relief lasting more than six months. As of mid-2026 there are no published randomized controlled trials of BPC-157 in humans for any indication. The first human safety signal is a 2025 pilot that gave intravenous BPC-157 (up to 20 mg) to two healthy adults without reported adverse effects — a two-person, uncontrolled study that provides only the thinnest of safety data. In short: the mechanistic and animal story is substantial and consistent; the human story is just beginning. Treat every benefit claim you read as an extrapolation from rodent work until human trials mature.

Talk to a BHRC physician about whether BPC-157 fits your situation →

How to Reconstitute BPC-157

BPC-157 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before it can be measured or injected. The following is educational reference material describing how reconstitution works; in a physician-supervised setting, mixing and dosing are prepared or directed by clinical staff.

What You Need

• A vial of lyophilized BPC-157 (commonly 5 mg; also sold as 10 mg)
• Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol as a preservative
• A reconstitution syringe (e.g., 3 mL) and a U-100 insulin syringe for dosing
• Alcohol swabs and a clean surface

Step-by-Step Reconstitution

1. Sanitize. Wash hands; wipe both vial stoppers (peptide and BAC water) with alcohol swabs and let dry.
2. Draw the diluent. Draw your chosen volume of bacteriostatic water into the reconstitution syringe (for a 5 mg vial, 2 mL is a common, easy-math choice).
3. Add slowly. Insert the needle into the peptide vial and let the water run slowly down the inside wall of the vial — do not spray it directly onto the powder.
4. Dissolve gently. Swirl gently; do not shake. The powder should dissolve into a clear solution within a minute or two.
5. Refrigerate. Store the reconstituted vial at 2–8°C.

Reconstitution Math Done For You

Concentration is simply the total peptide divided by the total water you added. The table below does the math for the most common combinations so you are not guessing.

Key relationship to remember: On a U-100 insulin syringe, “units” are hundredths of a milliliter (100 units = 1 mL). So at 2,500 mcg/mL, 10 units (0.1 mL) delivers 250 mcg, and 20 units (0.2 mL) delivers 500 mcg.

Dosing Calculation Examples (Syringe-Unit Chart)

Using the most common setup — a 5 mg vial reconstituted with 2 mL BAC water (2,500 mcg/mL) — here is exactly how far to draw the plunger on a U-100 insulin syringe for each target dose:

At this concentration a 5 mg vial provides twenty 250-mcg doses (or ten 500-mcg doses) — worth knowing when planning a cycle against the ~28-day post-mixing shelf life below.

Common Reconstitution Mistakes

A few avoidable errors change your dose without you realizing it:

• Forgetting that the concentration determines the units. The same “10 units” delivers 500 mcg at 5,000 mcg/mL but only 250 mcg at 2,500 mcg/mL. Always match your syringe chart to the exact amount of water you added.
• Using sterile or “sterile-for-injection” water instead of bacteriostatic water. Plain sterile water has no preservative and shortens usable shelf life; bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for multi-day vials.
• Spraying water directly onto the powder or shaking the vial. Peptides are delicate; forceful mixing can degrade them. Add water down the wall and swirl.
• Under- or over-filling the diluent. Adding 1.8 mL when you meant 2 mL shifts every subsequent dose. Draw the diluent carefully and read the syringe at eye level.

In a physician-supervised program these steps are handled or verified by clinical staff, which removes most of this error surface — one of the practical arguments for supervised use over DIY.

Storage and Shelf Life

Lyophilized (unmixed) BPC-157 is generally stored frozen or refrigerated and is stable for many months. Once reconstituted, keep it refrigerated at 2–8°C and use it within roughly 28 days — the benzyl alcohol in bacteriostatic water preserves the solution for about that long. Keep it out of light, never freeze a reconstituted vial, and discard if the solution becomes cloudy or discolored. Heat and repeated temperature swings are the enemies of peptide stability, so avoid leaving a vial out on the counter between doses and do not store it in the refrigerator door, where temperature fluctuates most.

BPC-157 Administration Guide

The following describes standard subcutaneous injection technique for educational reference. In a physician-supervised program, technique is taught and overseen by clinical staff.

Injection Site Selection

For systemic dosing, the subcutaneous fat of the abdomen (a couple of inches away from the navel) is the most common site, with the outer thigh and back of the arm as alternatives. Rotate sites to avoid irritation. For local dosing near an injury, the injection is placed subcutaneously in the tissue close to the affected tendon, ligament, or muscle, per provider direction.

Subcutaneous Injection Technique

1. Wipe the chosen site with an alcohol swab and let it dry.
2. Pinch a fold of skin to lift the subcutaneous fat away from muscle.
3. Insert the insulin needle at a 45–90° angle into the fold.
4. Depress the plunger slowly and steadily to deliver the measured dose.
5. Withdraw, apply gentle pressure with a clean swab, and dispose of the needle in a sharps container.

Local (Near-Injury) vs. Systemic Injection

Choosing between local and systemic delivery is a clinical decision. Local injection is favored by many practitioners for a discrete, identifiable soft-tissue injury on the theory of concentrating the peptide at the repair site; systemic dosing is used when the goal is broader (gut support, general recovery) or when the target tissue is not readily accessible to a safe subcutaneous injection. Neither approach has been validated head-to-head in human trials.

A practical caution on “local”: injecting near a joint, tendon sheath, or bursa is not the same as an intra-articular injection, and it should not be attempted blindly near delicate structures, nerves, or vasculature. When a truly intra-articular delivery is contemplated, that is a procedure for a clinician, not a self-administered one. For most people using BPC-157 with a local intent, a subcutaneous injection into the soft tissue in the general region of the injury — not into the joint or tendon itself — is what is meant.

Injection Comfort and Reducing Bruising

Small habits reduce the most common nuisance, injection-site bruising: use a fresh, fine-gauge insulin needle each time; let the alcohol dry fully before inserting; avoid visible surface veins; inject slowly; and apply brief, gentle pressure afterward rather than rubbing. Rotating sites — alternating sides of the abdomen or between abdomen, thigh, and arm — prevents local irritation from building up over a multi-week cycle. If a site becomes persistently sore, red, warm, or swollen, that is a reason to pause and contact your provider rather than to keep injecting the same spot.

Oral vs. Injectable BPC-157

This is one of the most common — and highest-intent — questions, so it deserves its own section rather than a footnote.

The Stability Question

BPC-157 is notable for its stability in gastric acid, which is the biological rationale behind oral capsules: unlike most peptides (which are degraded in the gut), a meaningful fraction is proposed to survive. That said, oral bioavailability and how much reaches the systemic circulation are not well characterized in humans, so “oral works exactly like injectable, everywhere in the body” is not an established claim.

When Oral May Make Sense

Oral BPC-157 is most logically matched to gut and GI-lining goals, where local exposure in the digestive tract is the point. For a localized tendon or ligament injury, injection near the site is the more common choice precisely because it aims to deliver the peptide where the injury is.

Oral Dosing Ranges

Optimal Timing for BPC-157 Administration

Once-Daily vs. Twice-Daily

Both once-daily and twice-daily (split morning/evening) schedules appear in practice. A single daily dose is simpler and adequate for many; splitting into two smaller doses is sometimes chosen for higher daily totals or to keep more consistent exposure across the day. Consistency day-to-day matters more than the exact hour.

Timing Around Food and Training

Oral BPC-157 is typically taken on an empty stomach. Injectable dosing is not strongly food-dependent; many people pick a fixed daily time for adherence. For injury or training contexts, some practitioners time a dose near a rehab or training session, though there is no strong human evidence that a specific clock time improves outcomes.

BPC-157 Cycle Length and Protocol Duration

Typical Cycle Lengths

A BPC-157 cycle is commonly 4–8 weeks. Shorter 4-week cycles are typical for milder issues; 6–8 weeks is used for more significant soft-tissue recovery. Longer continuous use is generally discouraged without a clear clinical reason and provider oversight — in part because of the theoretical angiogenesis concern discussed below, and in part because there is simply no long-term human safety data.

Cycling On and Off

Most protocols build in an off-cycle rather than running BPC-157 continuously. The intent is to use it as a defined course tied to a healing goal, evaluate the result, and stop — not to take it indefinitely. Whether and when to repeat a cycle is a provider decision informed by response and any monitoring.

What “Finishing a Cycle” Should Look Like

A well-run cycle has a defined endpoint decided in advance, not an open-ended “keep going until the vial runs out.” Practically, that means agreeing with your provider on the goal (for example, resolving a specific tendon issue or completing a defined gut-support course), the length (say, six weeks), and the checkpoint at the end where you assess whether the goal was met. If it was, you stop and reassess later; if it was not, that is important information — it may mean BPC-157 is not doing what you hoped, that the underlying problem needs a different intervention, or that further medical evaluation is warranted. Treating the peptide as a permanent supplement is precisely the pattern supervised programs try to avoid, both because of the theoretical angiogenesis concern and because indefinite use of an unproven agent is hard to justify.

BPC-157 Safety Profile and Potential Side Effects

Because human data is so limited, the honest summary is: BPC-157 has been reported to be well tolerated at the doses used, but its safety is not established by controlled human trials, and there is no long-term human safety record at all.

Commonly Reported Side Effects

• Injection-site reactions — redness, mild pain, bruising, or swelling
• Transient fatigue, lightheadedness, or headache reported anecdotally by some users
• Nausea or GI upset, more often noted with oral use
• Occasional reports of changes in blood pressure sensation (dizziness on standing)

These are largely anecdotal or drawn from small case reports; the absence of large trials means the true side-effect profile is not well characterized.

The Theoretical Cancer / Angiogenesis Concern

This concern deserves a direct, honest answer rather than being buried. BPC-157’s proposed benefits work partly through angiogenesis — the growth of new blood vessels — including upregulation of VEGF and its receptor VEGFR2 in animal models. VEGF/VEGFR2 signaling is also a pathway that many tumors use to build their own blood supply. That biological overlap is the basis of a legitimate theoretical question: could a pro-angiogenic peptide, in principle, support the growth of an existing or occult cancer?

What the evidence actually shows: no study has demonstrated that BPC-157 causes cancer in humans, and there is no human data quantifying any cancer risk. Equally, there is no in vivo evidence that it promotes tumor progression in intact animals at therapeutic doses — the concern is mechanistic and plausible, not demonstrated. The prudent, physician-supervised stance is straightforward: BPC-157 is generally avoided in anyone with an active malignancy, a recent cancer history, or undiagnosed suspicious symptoms, and its pro-angiogenic profile is precisely why open-ended, unsupervised use is discouraged. If you have any cancer history, this is a conversation to have explicitly with your physician before considering BPC-157.

Contraindications

• Active or recent cancer, or undiagnosed suspicious symptoms (see angiogenesis discussion above)
• Pregnancy and breastfeeding (no safety data)
• Known hypersensitivity to the peptide or to benzyl alcohol (in bacteriostatic water)
• Competitive athletes subject to anti-doping testing (WADA-prohibited — see regulatory section)

Drug and Supplement Interactions

Formal interaction studies do not exist. Two areas warrant particular provider attention: NSAIDs (BPC-157 is frequently discussed in the context of NSAID-related GI irritation, so combined use should be provider-directed) and any angiogenesis-modulating therapies (including certain cancer treatments), where the peptide’s pro-angiogenic activity could be biologically relevant. Always give your provider a full medication and supplement list.

Combining BPC-157 with Other Peptides and Therapies

BPC-157 is often discussed as part of a stack. The most famous pairing has a nickname, and it comes up constantly in patient questions.

The BPC-157 + TB-500 “Wolverine Stack”

The “Wolverine stack” is a community nickname for combining BPC-157 with TB-500 (a synthetic fragment related to thymosin beta-4), both of which have been studied for soft-tissue repair. The rationale is complementary intent: BPC-157 is often used with a local focus near an injury, while TB-500 is used systemically for its proposed effects on cell migration and inflammation signaling. It is not a branded drug, not a standardized clinical protocol, and not FDA-approved — and no controlled human study has evaluated the combination.

Wolverine Stack Dosing

A detailed TB-500 dosage guide is planned as a companion to this article — the two peptides are almost always researched together. Until then, treat the numbers above as an orientation to the conversation, not a protocol to self-run. [Internal note: link the TB-500 guide here once published.]

Can BPC-157 and TB-500 Be Mixed in One Syringe?

A frequent practical question is whether the two Wolverine-stack peptides can be drawn into the same insulin syringe to reduce the number of injections. In practice some people do combine them for convenience, but this is a decision for your provider — it affects nothing about the individual doses, only the number of injections, and it presumes both are reconstituted and compatible. When in doubt, injecting them separately removes any ambiguity about how much of each was delivered. Note again that TB-500 is dosed far less frequently than BPC-157 (a couple of times weekly versus daily), so on most days only BPC-157 is being injected anyway.

Other Common Pairings

BPC-157 is sometimes discussed alongside growth-hormone-axis peptides for a recovery-and-body-composition emphasis, such as CJC-1295 / Ipamorelin or Tesamorelin, and alongside mitochondrial-oriented peptides like MOTS-c. Any stack multiplies the unknowns and should be built by a physician, not assembled from forums. A key principle when stacking: change one variable at a time. Adding two new peptides simultaneously makes it impossible to attribute a benefit — or a side effect — to either one, which defeats the purpose of monitoring your response.

Peptide Comparison Matrix

Who Should Consider BPC-157 Therapy?

Potential Candidates

In a physician-supervised setting, people who ask about BPC-157 are often dealing with a stubborn soft-tissue injury (tendon, ligament, muscle), post-injury or post-surgical recovery goals, or GI-lining concerns, and want to understand a research-backed adjunct alongside standard care. The most appropriate candidate is someone who understands the evidence is early, wants medical oversight, and has no contraindications.

Who Should Avoid It

• Anyone with active, recent, or suspected cancer
• People who are pregnant or breastfeeding
• Competitive athletes subject to WADA/USADA testing
• Anyone unwilling or unable to use it under physician supervision
• People expecting a proven, FDA-approved treatment — BPC-157 is not that

Monitoring Progress and Adjusting Protocols

What to Track

Because there is no validated biomarker for BPC-157, monitoring is primarily clinical and functional: pain, range of motion, function, and — for gut use — symptom scores, tracked over the cycle. A provider may also monitor for any side effects and review overall health status. Keep a simple log of dose, site, date, and how you feel.

When to Adjust or Stop

Reasons to pause and consult your provider include no meaningful improvement by the end of a cycle, any concerning or persistent side effect, or any new symptom that warrants evaluation before continuing. Dose changes should be provider-directed, not self-titrated.

Setting Realistic Expectations

Two expectation traps are worth naming. The first is the “miracle peptide” framing that circulates online — the reality is that human efficacy is unproven, and BPC-157 is best thought of as a possible adjunct with an uncertain effect size, not a guaranteed fix. The second is impatience: soft-tissue healing takes weeks under the best circumstances, so judging a cycle after a few days is not meaningful. Give a provider-directed cycle its full defined length before concluding it did or did not help, and measure against functional milestones (less pain, more range of motion, return to activity) rather than day-to-day feel. If your expectations and the evidence do not line up, that gap is itself a good reason to talk with a physician before spending money and time on the peptide.

Is BPC-157 FDA-Approved? Legal & Regulatory Status (2026)

The short answer, dated: as of July 24, 2026, BPC-157 has no FDA approval for any medical indication. Its regulatory status is genuinely in flux right now, so the details below are stated as an evolving, dated snapshot — nothing here means BPC-157 is “now approved” or “now legal to freely buy.”

FDA Compounding Status: The 2023–2026 Timeline

What the April 2026 Category 2 Removal Actually Means

This is the most misread point in the whole topic, so read it carefully. Removal from Category 2 lifted a prohibition; it did not grant an approval. BPC-157 moved into a transitional, evaluative state — not onto the market as an approved drug. Before licensed 503A compounding pharmacies could legally produce it, the FDA would still have to add it to the 503A bulks list through formal rulemaking after the advisory review. Anyone telling you the April 2026 change means BPC-157 is “now legal to buy and use like a medication” is overstating what happened.

The July 2026 PCAC Review

The Pharmacy Compounding Advisory Committee met on July 23–24, 2026 (docket FDA-2025-N-6895; the public comment window closed July 22, 2026) to weigh whether BPC-157 belongs on the 503A bulk-substances list, with ulcerative colitis cited as the primary clinical interest driving the nomination. An advisory committee makes recommendations; it does not itself approve a drug or finalize compounding rules. The practical status remains: research-use supply exists, but the compounding pathway sits in a gray zone pending FDA action, and there is still no approved BPC-157 drug.

DEA and Athletic (WADA) Status

BPC-157 is not a DEA-scheduled controlled substance — it is not a narcotic and possession is not a criminal-scheduling matter. However, it is prohibited in sport by the World Anti-Doping Agency (WADA) under class S0 (non-approved substances), at all times, in and out of competition. Any athlete subject to WADA or USADA testing should treat BPC-157 as a banned substance. Because S0 covers substances with no current approval for human therapeutic use by any government regulatory health authority, BPC-157’s ambiguous compounding status does not exempt it — an athlete who tests positive cannot point to the 2026 reclassification as a defense.

Why “Research Use Only” Products Are a Warning Sign, Not a Loophole

Much of the BPC-157 sold online is labeled “for research use only” and “not for human consumption.” That label is a regulatory and quality warning, not a wink-and-nod formality. It means the product has not been manufactured, tested, or verified to the standards required for anything a person injects, and there is no guarantee of identity, purity, sterility, or dose accuracy. Contamination, under- or over-dosing, and mislabeled contents are real risks in the gray-market supply chain. This is a core reason BHRC’s position is physician-supervised care rather than self-sourced peptides: supervision addresses not only the dosing and candidacy questions but the fundamental question of what is actually in the vial.

Beverly Hills Rejuvenation Center does not sell raw or “research-use” peptides and does not provide BPC-157 for unsupervised use. Regulatory status is changing; the summary above is accurate as of July 24, 2026 and should be re-verified over time.

Conclusion

BPC-157 is one of the most interesting peptides in recovery-focused medicine — and one of the most misunderstood. The dosing conventions are reasonably consistent (250–500 mcg/day injectable, 4–8 week cycles, oral ~500–1,500 mcg/day for gut goals), the reconstitution math is simple once it is laid out (a 5 mg vial in 2 mL of water gives 10 units per 250 mcg), and the theoretical concerns — chiefly the angiogenesis question — are real enough to justify physician oversight rather than DIY experimentation. What is not settled is the human evidence: the science is overwhelmingly preclinical, and its U.S. regulatory status is actively evolving in 2026. That combination is exactly why BPC-157 belongs in a supervised medical conversation, where dose, candidacy, monitoring, and risk can be weighed for you specifically.

Schedule a Peptide Therapy Consultation with a BHRC physician →

Frequently Asked Questions About BPC-157 Dosing

What is the standard BPC-157 dosage?

The most commonly cited range is 250–500 mcg per day by subcutaneous injection, given once or twice daily over a 4–8 week cycle. Oral, gut-focused use is often higher (roughly 500–1,500 mcg/day). These are provider-directed ranges, not a universal prescription — actual dosing depends on the indication, your body weight, and clinical judgment.

How do I reconstitute a 5 mg BPC-157 vial and how many units is 250 mcg?

A common, easy-math approach is adding 2 mL of bacteriostatic water to a 5 mg vial, giving 2,500 mcg/mL. At that concentration, 250 mcg equals 0.1 mL, which is 10 units on a U-100 insulin syringe; 500 mcg equals 0.2 mL, or 20 units. In a supervised program, mixing and measuring are prepared or directed by clinical staff.

Is BPC-157 better taken orally or by injection?

It depends on the goal. Oral capsules are most logical for gut and GI-lining support, since the peptide is delivered directly to the digestive tract and is unusually stable in stomach acid. For a localized tendon, ligament, or muscle injury, injection near the site is the more common choice because it aims to concentrate the peptide where the injury is. Systemic uptake from oral dosing is not well characterized in humans.

How long should a BPC-157 cycle last?

Cycles are typically 4–8 weeks — around 4 weeks for milder issues and 6–8 weeks for more significant soft-tissue recovery, followed by an off-cycle. Continuous long-term use is generally discouraged without a clear clinical reason and physician oversight, partly because of the theoretical angiogenesis concern and partly because there is no long-term human safety data.

Does BPC-157 cause cancer?

No study has shown that BPC-157 causes cancer in humans, and there is no human data quantifying any cancer risk. The concern is theoretical: BPC-157 promotes angiogenesis (including VEGF/VEGFR2 signaling), a pathway many tumors also use. Because of that biological overlap, it is generally avoided in anyone with active, recent, or suspected cancer, and its pro-angiogenic profile is a key reason unsupervised open-ended use is discouraged.

What is the BPC-157 and TB-500 “Wolverine stack” dose?

A representative framing is BPC-157 at 250–500 mcg/day (often local, near an injury) combined with TB-500 dosed systemically — commonly around 2 mg loading twice weekly, then roughly 2 mg weekly for maintenance. It is a community nickname, not an FDA-approved or clinically validated protocol, and no controlled human study has evaluated the combination. It should only be considered under physician supervision.

What are the side effects of BPC-157?

Reported side effects are mostly mild and anecdotal: injection-site redness or bruising, transient fatigue, headache, lightheadedness, or GI upset (more with oral use). Because there are no large controlled human trials, the true side-effect profile is not well characterized, and there is no long-term human safety record.

How should BPC-157 be stored?

Unmixed lyophilized powder is stable refrigerated or frozen for months. Once reconstituted with bacteriostatic water, keep it refrigerated at 2–8°C and use it within about 28 days, protected from light. Do not freeze a reconstituted vial, and discard the solution if it becomes cloudy or discolored.

Is BPC-157 FDA-approved or legal in 2026?

As of July 24, 2026, BPC-157 has no FDA approval for any indication. The FDA placed it in 503A Category 2 in September 2023, then removed it from Category 2 in April 2026 — which lifted a prohibition pending review but is not an approval or authorization to compound freely. The Pharmacy Compounding Advisory Committee reviewed it on July 23–24, 2026 (docket FDA-2025-N-6895). It is not a DEA-scheduled substance, but it is prohibited in sport by WADA. This status is evolving and should be re-verified.

Do I need a doctor to use BPC-157?

Yes — it should be used only under physician supervision. BPC-157 is not an approved drug, its human evidence is limited, and it carries a theoretical angiogenesis/cancer consideration that requires a medical assessment of your history and candidacy. A provider can determine whether it is appropriate for you, direct the dose and cycle, and monitor your response. This guide is educational and is not a substitute for that evaluation.

Related Resources from BHRC

• Schedule a Peptide Therapy Consultation — physician-supervised peptide programs at BHRC
• CJC-1295 / Ipamorelin — growth-hormone-axis peptide often discussed for recovery and body composition
• Tesamorelin — GHRH analog studied for body composition
• MOTS-c — mitochondrial-derived peptide studied for metabolism and exercise capacity
• Semaglutide and Tirzepatide — GLP-1 therapies for metabolic goals
• TB-500 dosage guide — coming soon (companion to the Wolverine-stack section)

References

1. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533. PMCID: PMC8275860. doi:10.3389/fphar.2021.627533. Read on PMC
2. Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junction in Rats. Biomedicines. 2021;9(11):1547. PMCID: PMC8615275. doi:10.3390/biomedicines9111547. Read on PMC
3. Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. 2019;14:199. PMCID: PMC6604284. doi:10.1186/s13018-019-1242-6. Read on PMC
4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495. doi:10.1177/15563316251355551. PMID: 40756949. View article
5. Lee E, Burgess D. First-in-human intravenous BPC-157 safety pilot (up to 20 mg, n=2 healthy adults). Alternative Therapies in Health and Medicine. 2025. [PMID pending verification — see internal TODO.]
6. Sikiric P, et al. Body-protection-compound BPC-157 angiogenesis, VEGF/VEGFR2 and nitric-oxide-system mechanism reviews (University of Zagreb group). [Multiple papers; specific PMIDs pending verification — see internal TODO.]
7. U.S. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Pharmacy Compounding Advisory Committee materials, docket FDA-2025-N-6895 (meeting July 23–24, 2026).
8. World Anti-Doping Agency. Prohibited List — class S0, non-approved substances.

About the Author & Medical Reviewer

Sam Brooks is a health and wellness content writer for Beverly Hills Rejuvenation Center, specializing in evidence-based peptide and regenerative-medicine education.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.